Free Trial

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Cut to "Sell" at Wall Street Zen

Damora Therapeutics, Inc. Common Stock logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded DMRA from “Hold” to “Sell.” Despite the downgrade, analysts overall rate the stock “Buy,” with an average price target of $46.38.
  • Shares opened at $21.60, below their 50-day average of $22.19 and 200-day average of $25.61; the stock’s 52-week range is $15.76–$38.33.
  • The company reported a quarterly loss of $0.40 per share, narrower than the $0.52 loss analysts expected. CEO Jennifer Jarrett also bought 12,500 shares at an average price of $20.23.
  • MarketBeat previews the top five stocks to own by December 1st.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Monday, Wall Street Zen reports.

DMRA has been the subject of a number of other reports. Jefferies Financial Group began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a "buy" rating and a $50.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Wedbush reiterated an "outperform" rating and issued a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Weiss Ratings reissued a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Finally, Guggenheim began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, November 6th. They set a "buy" rating and a $59.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock has a consensus rating of "Buy" and an average price target of $46.38.

Read Our Latest Stock Report on DMRA

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of Damora Therapeutics, Inc. Common Stock stock opened at $21.60 on Monday. The stock has a market cap of $1.34 billion, a P/E ratio of -15.32 and a beta of 1.52. The stock's fifty day moving average is $22.19 and its 200 day moving average is $25.61. Damora Therapeutics, Inc. Common Stock has a one year low of $15.76 and a one year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.12. Analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current year.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett purchased 12,500 shares of the stock in a transaction that occurred on Friday, September 25th. The shares were bought at an average cost of $20.23 per share, with a total value of $252,875.00. Following the acquisition, the chief executive officer owned 512,500 shares in the company, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.40% of the company's stock.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth $303,000. Arizona State Retirement System bought a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $260,000. Seven Fleet Capital Management LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $7,398,000. Finally, Braidwell LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth $42,146,000. Institutional investors own 14.20% of the company's stock.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Further Reading

Analyst Recommendations for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Damora Therapeutics, Inc. Common Stock Right Now?

Before you consider Damora Therapeutics, Inc. Common Stock, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Damora Therapeutics, Inc. Common Stock wasn't on the list.

While Damora Therapeutics, Inc. Common Stock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines